Zydus Lifesciences announces execution of undertakings to tender over 22 lakh Amplitude Surgical shares

Written by Ruchika Sharma Published On 2025-04-17T14:00:14+05:30 | Updated On 17 April 2025 2:00 PM IST

Zydus Loses Patent Battle Over Bladder Drug Myrbetriq In US, Jury Trial Set for 2026

Ahmedabad: Zydus Lifesciences Limited has announced the execution of undertakings from 7 shareholders to tender 2,236,911 Amplitude Surgical shares, representing 4.7% of the company’s capital and voting rights by them.

This follows the announcement of the envisaged tender offer on March 11, 2025.

Considering the 85.6% of the capital that will be acquired by Zydus Lifesciences Limited from PAI Partners, the management of Amplitude Surgical and two minority shareholders, Zydus Lifesciences Limited will be in a position with these undertakings to acquire more than 90% of the capital and voting rights of Amplitude Surgical at the end of the tender offer.

These undertakings to tender 2,236,911 Amplitude Surgical shares, representing 4.7% of the company’s capital and voting rights, may be revoked in the event of a competing tender offer being filed by a third party, declared compliant and opened by the Autorité des marchés financiers.

The acquisition of the 85.6% block is expected to be completed by June 2025 and the draft tender offer will be filed with the Autorité des marchés financiers upon receipt of regulatory approvals. The opening of the tender offer will then be subject to the clearance decision of the Autorité des marchés financiers.

Medical Dialogues team had earlier reported that the Company had entered into exclusive negotiations to purchase from PAI Partners and Amplitude Surgical's management, as well as two minority shareholders, 85.6% of the share capital of Amplitude Surgical, at a price of €6.25 per Amplitude Surgical share (the “Block Acquisition”).

Zydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs.

zydus lifescienceszydus lifesciences newsamplitude surgicalPAI Partners

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751